For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
← Back to articles
Research topicsJuly 20, 20267 min read

Anxiety and mood peptides: what the research supports

Selank, Semax, and DSIP appear across the calm-and-focus conversation. Here is the evidence, and the female-data gap.

WP
Women'sPeptide Editorial
Research & evidence team
Key takeaways
  • Selank and Semax are Russian-developed neuropeptides studied in anxiety and cognition models, but their human data is limited and, across the indexed literature, none of it reported outcomes by sex.
  • DSIP is studied for sleep-architecture and HPA-axis signaling in preclinical systems, with no controlled human trials in women indexed for anxiety or mood endpoints.
  • For all three compounds, many studies included female subjects yet no sex-stratified outcomes were reported, so the female evidence is effectively unstudied.

Search for a calmer mind and the same short list of peptides keeps surfacing: Selank, Semax, and DSIP. They cluster in the anxiety, mood, and sleep conversation, often presented as gentler alternatives to conventional options. The mechanisms are real research questions, and the compounds have a genuine literature. What that literature does not have, on close reading, is much human data, and almost none of it broken out by sex. This page separates the studied mechanisms from the claims, and is explicit about the female gap.

Selank: a tuftsin analog for anxiolytic models

Selank is a synthetic heptapeptide analog of tuftsin, an immunomodulatory peptide, developed as a stabilized research material. In preclinical systems it has been studied for its influence on GABAergic signaling, brain-derived neurotrophic factor (BDNF) expression, monoamine balance, and enkephalin-degradation pathways, the mix of targets that puts it in anxiolytic and cognition research. Human data with Selank remains limited, and it is frequently studied alongside Semax.

Semax: an ACTH fragment in neuroscience research

Semax is a synthetic analogue of the ACTH fragment 4-10, developed in Russia in the 1980s. In preclinical models it has been studied for its relationship to BDNF and nerve-growth-factor expression and to dopaminergic and serotonergic signaling. Compared with Selank, its studied mechanism is relatively specific, characterized against defined pathways rather than acting broadly across receptor classes. Most human research comes from a small number of studies.

Across the indexed Selank and Semax literature, many studies included female subjects, yet none reported sex-stratified outcomes.Source: our evidence review of the indexed neuropeptide literature.

DSIP: sleep and stress-axis signaling

DSIP, delta sleep-inducing peptide, is a naturally occurring nonapeptide first identified in studies of sleep-related neurochemistry. In preclinical and in-vitro systems it has been studied for its modulatory relationship to sleep-architecture models, hypothalamic-pituitary-adrenal (HPA) axis signaling, neurotransmitter balance, and stress-response pathways. Because sleep and stress physiology are tightly linked, DSIP sits at the edge of the same mood conversation, though its indexed work is largely mechanistic.

The female data gap

The pattern across all three is consistent and worth stating plainly. For Selank and Semax, there is no menstrual-cycle interaction data, no pregnancy or lactation safety data, no hormonal-interaction data, and no data in perimenopausal or menopausal populations. Many studies included female subjects, but none reported outcomes by sex. DSIP's human record for anxiety and mood endpoints is thinner still. In this database's terms, the female evidence for these compounds is unstudied, a first-class, honest state, not a blank waiting to be filled with plausible-sounding extrapolation.

Not a dosing page

Some early studies report dose ranges for these compounds; none has an established therapeutic dose in most jurisdictions. Anything reported in the literature is research context only. This site does not publish personal dosing, protocols, or medical advice, and none of this is a substitute for care from a clinician.

If anxiety is affecting daily life

Persistent anxiety and mood changes are worth taking to a healthcare professional. Research-use peptides are not treatments for anxiety or any mental-health condition, and this page makes no such claim.

The calm-and-focus framing around these peptides runs well ahead of the human evidence, and that evidence, where it exists, was almost never analyzed in women. That is the honest map. For the full per-compound record of what was studied and in whom, see the Selank, Semax, and DSIP profiles, and for a closer look at the two most-compared members, the Selank vs Semax comparison.

Frequently asked questions

Have Selank, Semax, and DSIP been studied in women?

For all three compounds, the female evidence is effectively unstudied: many studies did include female subjects, but across the indexed literature none reported outcomes broken out by sex. That gap does not indicate safety or risk in women either way; it means no qualifying sex-stratified study has been found.

What has the research on Selank and Semax actually examined?

Both are Russian-developed neuropeptides studied largely in preclinical models: Selank, a tuftsin analog, has been examined in relation to GABAergic signaling, BDNF, and monoamine pathways, while Semax, an ACTH 4-10 analog, has been studied against BDNF, nerve-growth-factor, and dopaminergic and serotonergic signaling. Human data for both is limited, drawn from a small number of studies, and does not establish any clinical effect.

What is known about DSIP for sleep or mood?

DSIP has been studied for sleep-architecture and HPA-axis signaling in preclinical systems. The indexed literature contains no controlled human trials in women for anxiety or mood endpoints, so its effects on those outcomes in women remain unstudied.

Can this page tell me how to dose one of these peptides?

No. This site does not provide personal dosing, titration, or protocols, and for these compounds no female dose-response data exists in the indexed literature. All of this material is research-use-only, and decisions belong with a qualified clinician; anyone pregnant, breastfeeding, or trying to conceive should consult an OB-GYN or qualified clinician.

Compounds referenced

Keep reading

Ready to take the next step?

Now that you've seen what the evidence does and doesn't say, find research-grade material from our verified supplier, or ask Vera for a sourced answer on any compound.

Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Sources

  1. PubMed-indexed preclinical studies on Selank, tuftsin analogs, and GABAergic and BDNF signaling
  2. Preclinical and early clinical literature on Semax and neurotrophic signaling
  3. Neuroendocrinology literature on DSIP, sleep architecture, and HPA-axis regulation
  4. Endocrinology literature on sex differences in stress and neuropeptide systems
  5. Our internal evidence review tracking female enrollment and sex-stratified reporting across these compounds
  6. Functional Connectomic Approach to Studying Selank and Semax Effects (2020). PubMed-indexed. View source ↗
  7. PubMed search for indexed research on this topic. View source ↗

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe. Some outbound links are affiliate links.